Citations (9)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (2)
Elżbieta Iskierka-Jażdżewska, Federico Canzian, Anna Stępień, Alessandro Martino, Daniele Campa, Angelica Stein, Małgorzata Krawczyk-Kuliś, Malwina Rybicka-Ramos, Sławomira Kyrcz-Krzemień, Aleksandra Butrym, Grzegorz Mazur, Artur Jurczyszyn, Daria Zawirska, Norbert Grząśko, Waldemar Tomczak, Edyta Subocz, Marzena Wątek, Marcin Pasiarski, Marcin Rymko, Małgorzata Całbecka, Agnieszka Druzd-Sitek, Jan Walewski, Marcin Kruszewski, Małgorzata Raźny, Jan Maciej Zaucha, Marek Dudziński, Paweł Gaj, Tadeusz Robak, Krzysztof Warzocha & Krzysztof Jamroziak. (2020) Cereblon (CRBN) gene polymorphisms predict clinical response and progression-free survival in relapsed/refractory multiple myeloma patients treated with lenalidomide: a pharmacogenetic study from the IMMEnSE consortium. Leukemia & Lymphoma 61:3, pages 699-706.
Read now
Read now
Giuseppina Uccello, Annamaria Petrungaro, Carla Mazzone, Anna Grazia Recchia, Rosa Greco, Francesco Mendicino, Eugenio Lucia, Ernesto Vigna, Fortunato Morabito & Massimo Gentile. (2017) Pomalidomide in multiple myeloma. Expert Opinion on Pharmacotherapy 18:2, pages 133-137.
Read now
Read now
Articles from other publishers (7)
Felipe de Arriba de la Fuente, Carmen Montes Gaisán & Javier de la Rubia Comos. (2022) How to Manage Patients with Lenalidomide-Refractory Multiple Myeloma. Cancers 15:1, pages 155.
Crossref
Crossref
Grace Lassiter, Cole Bergeron, Ryan Guedry, Julia Cucarola, Adam M. Kaye, Elyse M. Cornett, Alan D. Kaye, Giustino Varrassi, Omar Viswanath & Ivan Urits. (2021) Belantamab Mafodotin to Treat Multiple Myeloma: A Comprehensive Review of Disease, Drug Efficacy and Side Effects. Current Oncology 28:1, pages 640-660.
Crossref
Crossref
Adeela Mushtaq, Ahmad Iftikhar, Hamza Hassan, Midhat Lakhani, FNU Sagar, Ahmad Kamal, Umar Zahid, Zeeshan Ali, Faryal Razzaq, Muhammad Abu Zar, Syeda Fatima Hassan, Ahmad Safdar, Sreejata Raychaudhuri & Faiz Anwer. (2019) Pomalidomide-Based Regimens for Treatment of Relapsed and Relapsed/Refractory Multiple Myeloma: Systematic Review and Meta-analysis of Phase 2 and 3 Clinical Trials. Clinical Lymphoma Myeloma and Leukemia 19:7, pages 447-461.
Crossref
Crossref
Meletios DimopoulosKatja WeiselNiels W.C.J. van de DonkKarthik RamasamyBarbara GamberiMatthew StreetlyMassimo OffidaniFrank BridouxJavier de la RubiaMaria-Victoria MateosAntonio ArdizzoiaElisabeth KueenburgShona CollinsAntonia Di MiccoBarbara RosettaniYan LiPamela BaconPieter Sonneveld. (2018) Pomalidomide Plus Low-Dose Dexamethasone in Patients With Relapsed/Refractory Multiple Myeloma and Renal Impairment: Results From a Phase II Trial. Journal of Clinical Oncology 36:20, pages 2035-2043.
Crossref
Crossref
Pauline Gueneau, Marie-Lorraine Chretien, Amelie Cransac-Miet, Ludwig Serge Aho, Ingrid Lafon, Camille Favennec, Julien Guy, Denis Caillot & Mathieu Boulin. (2018) Efficacy, safety, and cost of pomalidomide in relapsed and refractory multiple myeloma. European Journal of Haematology 100:5, pages 518-525.
Crossref
Crossref
Sheridan M. Hoy. (2017) Pomalidomide: A Review in Relapsed and Refractory Multiple Myeloma. Drugs 77:17, pages 1897-1908.
Crossref
Crossref
Nicola Maciocia, Andrew Melville, Simon Cheesman, Faye Sharpley, Karthik Ramasamy, Matthew Streetly, Matthew Jenner, Reuben Benjamin, Steve Schey, Paul Maciocia, Rakesh Popat, Shirley D'sa, Ali Rismani, Aviva Cerner, Kwee Yong & Neil Rabin. (2017) Real-world use of pomalidomide and dexamethasone in double refractory multiple myeloma suggests benefit in renal impairment and adverse genetics: a multi-centre UK experience. British Journal of Haematology 176:6, pages 908-917.
Crossref
Crossref